Premature infants with parenteral nutrition-associated cholestasis (PNAC) require careful nourishment. Omegaven is the first and only 100% fish oil lipid emulsion in the US for pediatric patients with PNAC.1
- Omegaven is a source of calories and fatty acids in pediatric patients with PNAC1
- Fish oil is the newest type of lipid to be introduced into PN products1
- Fish oil is rich in omega-3s1

Features of Omegaven
Omegaven became commercially available in November of 2018; it was previously available only for compassionate care. Fresenius Kabi was widely aware of the need for this product to be more broadly available to pediatric patients and worked hard to secure the necessary clinical evidence to support FDA approval.
- Patients receiving Omegaven achieved age-appropriate growth1,2
- Omegaven-treated patients experienced improvement in liver function parameters1,2
- Direct or conjugated bilirubin levels were lowered1,2
- Contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)1
EPA and DHA (omega-3 fatty acids) are considered to be important for healthy development of infants due to their physiological roles3,4
May be considered conditionally essential for growth and development5,6
Important structural elements of cell membranes4
The mean content of the two major fatty acid components in 10 g/100 mL of Omegaven are 2.0 g EPA and 1.9 g DHA1
Indications and limitations of use
Indication:
Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).1
Limitations of Use:
Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients. It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6: omega-3 fatty acid ratio of the product.1
Understanding PNAC
PNAC is the onset of liver disease in the context of the administration of PN in patients with temporary or permanent intestinal failure.7 It is most commonly defined as direct or conjugated bilirubin greater than 2 mg/dL in patients who receive PN >2 weeks.8-11 Other terms commonly used include intestinal failure-associated liver disease (IFALD) and parenteral nutrition-associated liver disease (PNALD).
Incidence of PNAC increases with longer exposure to PN.12 The average incidence rate of PNAC in neonates and infants is 29.9%.11
PNAC risk factors may include prematurity, low birth weight, lack of enteral feeding, necrotizing enterocolitis, recurrent sepsis, and factors relevant to PN.11-13
ORDERING INFORMATION | ||
---|---|---|
NDC | 63323-205-50 | 63323-205-00 |
Bottle Size | 50 mL | 100 mL |
Bottles/Case | 10 | 10 |
Omegaven resources
Explore additional Omegaven materials by visiting our Resource Center.
For Consumers
OMEGAVEN (fish oil triglycerides) injectable emulsion, for intravenous use
IMPORTANT SAFETY INFORMATION
These highlights do not include all the information needed to use OMEGAVEN safely and effectively. To learn more about OMEGAVEN for your child, talk to your child’s healthcare provider. OMEGAVEN is available by prescription only. The FDA-approved product labeling can be found at www.freseniuskabinutrition.com/OmegavenPI.
What is OMEGAVEN?
- A fish oil-based intravenous lipid emulsion that is a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
- Does not prevent PNAC.
- It has not been demonstrated that the clinical outcomes seen in pediatric patients are a result of the omega-6:omega-3 fatty acid ratio of the product.
- The hourly infusion rate should not exceed 1.5 mL/kg/hour
For Consumers
OMEGAVEN (fish oil triglycerides) injectable emulsion, for intravenous use
IMPORTANT SAFETY INFORMATION
These highlights do not include all the information needed to use OMEGAVEN safely and effectively. To learn more about OMEGAVEN for your child, talk to your child’s healthcare provider. OMEGAVEN is available by prescription only. The FDA-approved product labeling can be found at www.freseniuskabinutrition.com/OmegavenPI.
What is OMEGAVEN?
- A fish oil-based intravenous lipid emulsion that is a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
- Does not prevent PNAC.
- It has not been demonstrated that the clinical outcomes seen in pediatric patients are a result of the omega-6:omega-3 fatty acid ratio of the product.
- The hourly infusion rate should not exceed 1.5 mL/kg/hour